VANCOUVER, BC, Feb. 3, 2022 – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE”), a leader in advanced proprietary technology for mental health care and research in psychedelics, announced today the hiring of Dr. Clare Purvis, formerly Headspace Inc.’s Vice President of Clinical Product and Content Development, for the Company’s newly created role of Chief Product Officer to focus on building and expanding the reach of iSTRYM, its digital therapeutics platform.
“As care becomes more personalized, the need has never been greater for high quality, scalable digital therapeutics in the mental healthcare space, and I’m excited to join the MINDCURE team at the forefront of the progress being made,” said Dr. Purvis adding, “iSTRYM has proven itself in a fast-growing market and I believe it has the potential to become a dominating force as the product of choice for clinics utilizing technology-assisted therapies.”
While working at Headspace, Dr. Purvis was on the Executive Leadership Team responsible for clinical and scientific strategy, helping to set the company’s overall strategy and overseeing new product development in mental and behavioral health starting in 2019. She currently serves as a Clinical Advisory Board member at Brightline, which provides a technology-driven approach to pediatric behavioral health.
“It’s a pivotal and proud moment in the trajectory of MINDCURE as we welcome Dr. Purvis to the team. Clare’s experience, expertise and reputation as a thought leader and science-backed leader in the fast-growing digital mental health space will be an invaluable addition to MINDCURE’s growth in the mental healthcare industry,” said MINDCURE’s President and CEO Kelsey Ramsden. “As MINDCURE pushes forward to make Mental WealthTM a reality for more people, Clare will be leading the charge on delivering a truly transformational and high value experience for both therapists, patients and ultimately, payers,” Ramsden added.
MINDCURE’s product solution, iSTRYM, is expanding to cover a broader market which will include clinics that operate in both psychedelic-assisted psychotherapy and general psychotherapy and psychiatry. It is for this purpose that MINDCURE is introducing the role of Chief Product Officer to deliver the above initiatives. After successfully creating its initial product as Chief Technology Officer, Geoff Belair will spearhead the migration of our technology team to an engineering division, with focus on data strategy and build-out of MINDCURE’s AI models supporting the product. In his new role as Vice President of Engineering, Mr. Belair will report to the CPO and will be working closely with Dr. Purvis to ensure success as MINDCURE drives to commercialization.
“I would like to thank Mr. Belair for his visionary architecture of the platform and look forward to his continued service in this new role,” said MINDCURE’s President and CEO Kelsey Ramsden.
Dr. Purvis is a licensed clinical psychologist and she received her Doctorate in Psychology from the PGSP-Stanford Consortium where she trained in the Stanford Department of Psychiatry and Behavioral Sciences. She serves as an Affiliated Scholar at Stanford University’s Clinical Excellence Research Center, where she provides consultation on the use of technology to make great healthcare more affordable.
MINDCURE is also announcing that Daniel Herrera, current Vice President, Growth and Strategic Partnerships, has been promoted to the role of Chief Growth Officer as result of his exceptional performance to date. His continued work in this position will drive MINDCURE forward as we near commercialization of iSTRYM and plan for significant growth in the coming years.
ISTRYM is currently partnered with 20 clinics in North America during its closed beta roll out. Full commercialization of the platform is expected in Q2 of 2022. Mental healthcare therapists and psychiatrists wishing to get access to the platform this year are currently being welcomed and onboarded in priority sequence.
About Mind Cure Health Inc.
MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based psychedelic-assisted therapies globally. Learn more at mindcure.com, and follow us on LinkedIn, Facebook, Twitter, and Instagram.
On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Certain information presented in this news release may constitute “forward-looking information” within the meaning of applicable securities laws regarding MINDCURE and its business. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases.
Forward-looking information is based on a number of key expectations and assumptions made by management of MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE’s business; the Company will develop its products as expected and that they will attain the outcomes anticipated; there will be a demand for MINDCURE’s products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that strategic partnerships entered by the Company will create the opportunities and outcomes anticipated; that MINDCURE will advance wellness worldwide; and that HIPAA compliance certification will have a positive impact on the commercial deployment of iSTRYM.
Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information inherently entails known and unknown risks and uncertainties about the future and actual results and involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Although MINDCURE has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those described in forward-looking information presented, there may be other factors that cause results, performance or achievements to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements as no forward-looking information can be guaranteed.
Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and MINDCURE does not undertake any obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.
The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.
SOURCE Mind Cure Health Inc.